Pure Global AI
NCT06352424Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

A Single-dose, Randomized, Placebo-controlled Phase I Study on the Effects of a Subcutaneous Dose of BI 1820237 and BI 456906, and Combination Thereof on Functional MRI Measurements in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Single-blind, Cross-over Design)
Boehringer IngelheimPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
BI 456906
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Boehringer Ingelheim
Timeline & enrollment
Phase
Phase 1
Start date
Apr 15, 2024
End date
Dec 09, 2024
Enrollment
24 participants
Primary outcome

Blood Oxygen Level Dependent (BOLD) signal changes following treatment with single dose of BI 1820237 alone, BI 456906 alone, and combination of BI 1820237 + BI 456906 versus placebo

Summary

The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906
 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06352424
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06352424 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.